P
Protara Therapeutics, Inc. (TARA)
NGM – Real Time Price. Currency in USD
4.12
+0.12 (3.00%)
At close: Jun 26, 2026, 4:00 PM EDT
4.20
+0.08 (1.94%)
After-hours: Jun 26, 2026, 7:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.12
+0.12 (3.00%)
At close: Jun 26, 2026, 4:00 PM EDT
4.20
+0.08 (1.94%)
After-hours: Jun 26, 2026, 7:31 PM EDT
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
| Name | Position |
|---|---|
| Carla Beckham M.D., Ph.D. | Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Chief R&D Officer |
| Dr. Leonardo Viana Nicacio M.D. | Chief Medical Officer |
| Dr. Neal D. Shore F.A.C.S., M.D. | Medical Director of START Carolinas/ Carolina Urologic Research Center |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Mr. Jesse Shefferman |
| Date | Type | Document |
|---|---|---|
| 2026-06-15 | 8-K | ea0294030-8k_protara.htm |
| 2026-05-14 | S-3 | ea0289983-s3_protara.htm |
| 2026-05-13 | 8-K | ea0288581-8k_protara.htm |
| 2026-05-13 | 10-Q | ea0287944-10q_protara.htm |
| 2026-04-28 | DEFA14A | ea0286228-05.htm |
| 2026-04-28 | DEF 14A | ea0286228-04.htm |
| 2026-04-28 | ARS | ea0286228-03.pdf |
| 2026-04-17 | PRE 14A | ea0286228-01.htm |
| 2026-03-30 | 8-K | ea0283949-8k_protara.htm |
| 2026-03-10 | 8-K | ea0280404-8k_protara.htm |
| Co-founder, CEO, President & Director |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
| Ms. Mary J. Grendell J.D. | General Counsel & Corporate Secretary |